Clinical Trials

11 enrolled

Breast Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3 Terminated

63 enrolled 22 charts

Breast Neoplasms

NCT00251433 2023-03-31

GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer

53 enrolled

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

7 enrolled 6 charts

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT00508274 2021-09-21

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Phase 3 Terminated

52 enrolled 12 charts

Breast Neoplasms

NCT01118975 2019-11-13

GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers

Phase 1/2 Terminated

12 enrolled 6 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01891357 2019-09-17

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

64 enrolled 7 charts

Carcinoma, Ductal, Breast

NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

62 enrolled 25 charts

Breast Neoplasms, Diarrhea, Neoplasms

NCT00759642 2019-07-01

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

33 enrolled 7 charts

Breast Neoplasms

NCT00225758 2018-07-27

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

27 enrolled 5 charts

Breast Neoplasms

NCT01934894 2017-07-02

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

11 enrolled 7 charts

Metastatic Breast Cancer With Intracranial Metastases

NCT01868503 2017-06-26

Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer

7 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00496366 2017-03-21

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

11 enrolled 8 charts

Breast Neoplasms

NCT00634088 2016-03-10

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

13 enrolled 13 charts

Breast Neoplasms

NCT01534455 2016-02-10

Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)

43 enrolled

Breast Neoplasms

NCT02131506 2016-02-02

CAELYX

11 enrolled

Breast Neoplasms

NCT01495884 2015-10-26

The Myocet/Lapatinib Study. ICORG 10-03, V5

Phase 1/2 Terminated

11 enrolled

Her2 Positive Metastatic Breast Cancer

NCT00437073 2015-10-15

Brain Metastases In ErbB2-Positive Breast Cancer

22 enrolled 8 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00754702 2015-09-28

Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer

16 enrolled

Breast Neoplasms

NCT01161368 2015-08-13

A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients

9 enrolled

Breast Neoplasms

NCT00857714 2015-07-08

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

Phase NA Terminated

1 enrolled 9 charts

Carcinoma, Intraductal, Noninfiltrating

NCT01238029 2014-11-21

CELAVIE

12 enrolled

Breast Neoplasms

NCT00756470 2014-11-17

Phase II Neoadjuvant in Inflammatory Breast Cancer

15 enrolled 10 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00709618 2014-07-14

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

44 enrolled 11 charts

Breast Neoplasms

NCT01477060 2014-02-20

Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer

32 enrolled

Breast Neoplasms

NCT00903656 2013-12-24

Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

24 enrolled

Breast Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

60 enrolled

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT01658358 2013-02-27

ErbB2 Positive Metastatic Breast Cancer

Phase 1/2 Terminated

15 enrolled

Breast Neoplasms

NCT00499681 2012-08-10

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

6 enrolled 8 charts

Breast Neoplasms

NCT00479856 2012-06-05

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

9 enrolled 7 charts

Breast Neoplasms

NCT00820924 2012-03-28

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

23 enrolled

Breast Neoplasms

NCT00657137 2012-03-15

APRiCOT-B

12 enrolled